Butlin C R, Neupane K D, Failbus S S, Morgan A, Britton W J
Anandaban Leprosy Hospital, Kathmandu, Nepal.
Int J Lepr Other Mycobact Dis. 1996 Jun;64(2):136-41.
Although multidrug therapy (MDT) was introduced into Nepal in 1983, the MDT coverage only recently exceeded 67%. In view of the large number of patients who were still receiving dapsone monotherapy, it is relevant to investigate the current levels of dapsone and rifampin resistance. The study was undertaken at a leprosy referral hospital near Kathmandu. Over a 5 1/2-year period, 157 leprosy patients with a bacterial index (BI) > or = 2.0 were investigated for drug resistance according to the method of Rees. Among previously untreated cases, 6% of 88 isolates showed low-dose dapsone resistance; among previously treated patients with a presumed relapse, 47% of 34 isolates demonstrated dapsone resistance. In the remaining 35 cases there was no growth in control mice. Rifampin resistance was not confirmed in any case.
尽管1983年多药疗法（MDT）就已引入尼泊尔，但直到最近MDT覆盖率才超过67%。鉴于仍有大量患者接受氨苯砜单一疗法，因此研究当前氨苯砜和利福平耐药水平很有必要。该研究在加德满都附近的一家麻风病转诊医院开展。在5年半的时间里，按照里斯的方法，对157名细菌指数（BI）≥2.0的麻风病患者进行了耐药性调查。在既往未治疗的病例中，88株分离菌株中有6%显示对低剂量氨苯砜耐药；在既往接受治疗且推测为复发的患者中，34株分离菌株中有47%表现出氨苯砜耐药。其余35例在对照小鼠中未生长。在任何病例中均未确认利福平耐药。
